Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 169 matching trials from the live ClinicalTrials.gov search.
Conditions
ADHD, Bipolar Disorder
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Interventions
Centanafadine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Adhansia XR, Concerta
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
12 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
35
States / cities
Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
PDC-1421 Capsule
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Conditions
Attention Deficit Hyperactivity Disorder, Substance Use Disorder
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Music-Based Binaural Beats Stimulation, Music Listening Without Binaural Beats
Behavioral
Lead sponsor
California State University, San Bernardino
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Bernardino, California
Completed No phase listed Observational Accepts healthy volunteers Results available

Association Between Smoking, Brain Activity, Genes, and ADHD

NCT00915798
Conditions
Smoking, Withdrawal Nicotine, ADHD
Interventions
Cigarette smoking, Abstinence
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Santa Ana, California
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Vayarin®, Placebo
Other
Lead sponsor
Enzymotec
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Marietta, Georgia • Mount Kisco, New York • New York, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PRC-063, lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN SR, Matching placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
Conditions
Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD, ASD, Alcohol Abuse/Dependence, Alcohol Addiction, Alcohol and Other Drug Use Disorders, Alcohol and Other Substance Use Prevention, Gambling Addiction, Gambling Disorder, Sex Abuse, Sex Behavior, Sex Crimes, Sex Disorder, Sex Disorders, Gender Dysphoria, Adult, Eating Behavior Disorders, Narcotic-Related Disorders, Narcotic Addiction, Narcissism, Psychiatric Disorder, Psychedelic Effects in Healthy Volunteers, Psychedelic Experiences, Psychedelic Drug Dependence, Marijuana Use Disorder, Marijuana Abuse and Dependence, Smoking (Tobacco) Addiction, Smoking Among Youth, Smoking Abstinence, Abstinence, Sex, Opiate Substitution Treatment, Opioid Abuse (Disorder), Opioid Abuse and Addiction, Cocaine Abuse, MDMA ('Ecstasy'), Addiction Disorders, Homeless and Low Incomes People, Refugees, Homelessness, Reliability and Validity, Anger Problems, Child Abuse, Sexual
Interventions
AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
Behavioral
Lead sponsor
Veterans Recovery Network Inc.
Other
Eligibility
17 Years to 99 Years
Enrollment
1,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2045
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
ADHD
Interventions
ADHD Therapy, Control Therapy
Device
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Garden Grove, California • Sacramento, California + 10 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Digital Treatment
Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Garden Grove, California • Lauderhill, Florida + 11 more
Conditions
ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
Interventions
MG01CI (1400 mg), placebo
Drug
Lead sponsor
Alcobra Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Gainesville, Florida • South Miami, Florida • Libertyville, Illinois + 15 more
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

NCT02756286
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NAT electroencephalography (EEG) test
Other
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 40 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Berkeley, California • Los Angeles, California • Portland, Oregon
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more
Conditions
Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions
Dyanavel XR, Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester Hills, Michigan
Conditions
Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions
ALKS 7290, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Little Rock, Arkansas • Chino, California • Clermont, Florida + 20 more
Conditions
Attention Deficit Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
21
States / cities
Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more